Join our daily newsletter At The Bell to receive exclusive market insights
- Pacific Edge (PEB) receives a signed agreement from Te Whatu Ora Southern for the use of its non-invasive Cxbladder genomic biomarker tests
- Cxbladder is a urine test which aims to detect and manage bladder cancer, and allows patients to skip the discomfort of an invasive cystoscopy examination
- The cancer diagnostics company completed a commercial agreement with the Southern District Health Region (SDHR) for the use of its biomarker tests back in July 2022, which would see Te Whatu Ora deploy Cxbladder Triage into Otago and Southland’s primary care setting
- Pacific Edge can now begin implementing its device into hospitals
- Company shares last traded at 47.5 cents at 11:21 am AEDT
Pacific Edge (PEB) has received a signed agreement from Te Whatu Ora Southern for the use of its non-invasive Cxbladder genomic biomarker tests.
Cxbladder is a non-invasive genomic urine test optimised for the detection and management of bladder cancer.
The cancer diagnostics company completed a commercial agreement with the Southern District Health Region (SDHR) for the use of its biomarker tests back in July 2022.
The contract would see the SDHR, which goes by Te Whatu Ora, and assumes the administrative healthcare responsibility for 326,000 people across Otago and Southland, deploy Cxbladder Triage into New Zealand’s primary care setting.
The agreement with SDHR offered 15 of New Zealand’s 20 administrative health regions, covering more than 75 per cent of the country’s population, access to the test via public healthcare.
Under the primary care model, general practitioners would be able to order the product to help safely “de-intensify” clinical workup for patients presenting with hematuria. In many cases this would also reduce the need for secondary referral and an invasive cystoscopy.
“An important benefit for patients is that it can safely spare patients from the potential risks and discomfort of an invasive cystoscopy examination, meaning Cxbladder is a positive change in the standard of patient care,” VP Commercial for the Asia Pacific region at Pacific Edge Brent Pownall said.
Despite Pacific Edge advising the market the signing of the contract had been delayed back in September 2022, it has now received the signed and executed agreement, and can begin implementing its device into hospitals.
Company shares last traded at 47.5 cents at 11:21 am AEDT.
